Norwood, MA (PRWEB) April 04, 2013
Infinata, part of the Financial Times Group of companies, is a leading provider of business intelligence solutions including BioPharm Insight™, BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. Today the company announced the launch of its corporate-wide Clear Quality initiative to optimize reliability and usability of its cloud-based solutions.
With more than 250 individual quality checks and processes, Clear Quality formalizes Infinata’s commitment to ensuring every one of its hundreds of thousands of data points is as current and accurate as possible for three primary goals:
“Infinata was founded over a decade ago by data aggregation and integration experts,” said Ruth McHenry, Managing Director of Infinata. “As the big data requirements of global biopharmaceutical and financial services industries mature, simply providing data is no longer sufficient. Infinata stays ahead of this curve by innovating with services, features and analysis which provide practical answers based on trustworthy data rather than ambiguous facts and figures.”
Continued McHenry, “Clear Quality is a robust, formal and transparent commitment to customers who rely on Infinata solutions for the information edge they need to gain a competitive advantage and dominate their global markets.”
To learn more about Infinata’s solutions, visit http://www.infinata.com.
About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, part of the Financial Times Group of companies and a division of Pearson plc.
Read the full story at http://www.prweb.com/releases/2013/4/prweb10599354.htm.
Copyright©2012 Vocus, Inc.
All rights reserved